Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence†
Article first published online: 2 MAY 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 48, Issue 2, pages 497–507, August 2008
How to Cite
Shi, Y.-H., Ding, W.-X., Zhou, J., He, J.-Y., Xu, Y., Gambotto, A. A., Rabinowich, H., Fan, J. and Yin, X.-M. (2008), Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology, 48: 497–507. doi: 10.1002/hep.22393
Potential conflict of interest: Nothing to report.
- Issue published online: 29 JUL 2008
- Article first published online: 2 MAY 2008
- Accepted manuscript online: 2 MAY 2008 12:00AM EST
- Manuscript Accepted: 15 APR 2008
- Manuscript Received: 7 FEB 2008
- US NIH. Grant Numbers: R01CA83817, CA111456
- National Natural Science Foundation of China. Grant Number: 30571801
- Shanghai National Natural Science Foundation. Grant Number: 05ZR14027
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. Despite significantly improved diagnosis and treatment in recent years, the long-term therapeutic effect is compromised by the frequent recurrence and metastasis, of which the molecular mechanisms are not fully understood. Our initial studies in established HCC cell lines with different metastatic capabilities indicated a correlation of metastasis with the resistance to apoptosis and therefore the ability to survive in stressed conditions. Subsequent investigation revealed that increased expression of X-linked inhibitor-of-apoptosis protein (XIAP) was correlated with the resistance to apoptosis and enhanced invasiveness in vitro, which could contribute to increased metastatic foci in vivo. Furthermore, we found that nearly 90% of clinical samples from advanced HCC patients expressed high levels of XIAP. Patients with XIAP-positive tumors had a significantly increased risk of relapse, which resulted from metastasis after total liver resection and orthotopic liver transplantation. Indeed, XIAP expression could be an independent prognostic factor for predicting disease-free survival rate and overall survival rate of these patients. XIAP expression was also highly correlated with advanced cases that exceeded the Milan criteria and could be a prognostic factor for disease-free survival in these patients as well. Conclusion: Our studies have shown an important molecule in controlling HCC metastasis, defined a biomarker that can be used to predict HCC recurrence and patient survival after treatment, and suggest that XIAP can be a molecular target subject to intervention to reduce metastasis and recurrence. (HEPATOLOGY 2008;48:497–507.)
Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide.1 The prognosis of HCC has been significantly improved in recent years because of earlier diagnosis and more effective treatments. However, tumor recurrence and metastasis are still the major obstacles for long-term survival.2, 3 Although liver resection followed by liver transplantation is considered a curative treatment for HCC, the overall recurrence rate attributable to distant metastasis or intrahepatic reappearance could be as high as 65% and 43% after the procedure, respectively.4 Therefore, elucidating the molecular mechanism of HCC recurrence is important for the development of more effective treatment modalities.
The process of metastasis can be summarized as a series of sequential events that include intravasation, transport via the circulatory system, trapping at a secondary site, extravasation, and growth in the secondary site.5 Metastasis is actually an inefficient process by which only a small percentage of tumor cells that leave the primary site could survive to form metastatic foci at new sites.6 It is likely that metastasis can fail at any given stage of the process because of cell destruction by the immune system, blood flow turbulence, hypoxia, nutrition deprivation, or unsuitable tissue microenvironment. The susceptibility of tumor cells to death during metastasis can directly affect the efficiency of metastasis.7 Tumor cells with higher metastatic potentials are likely more resistant to cell death. Thus, it is critical to explore the molecular relationship between cell survival and metastasis.
It is well known that deregulated apoptosis contributes to carcinogenesis, abnormal cell differentiation, and resistance to chemotherapy. Multiple mechanisms could contribute to enhanced survival and reduced apoptosis in tumor cells, among which the control of caspase activation would be the key. Depending on how caspases are activated through the intrinsic or extrinsic pathway, cancer cells may develop different means to suppress the activation. The inhibitor-of-apoptosis proteins (IAPs) represent a large family of endogenous caspases inhibitors, which include X-linked IAP (XIAP), c-IAP1, c-IAP2, and Survivin.8 Among them, XIAP is perhaps the most relevant and most potent caspase inhibitor.9 XIAP could suppress the activation of an initiator caspase, caspase-9, and the effector caspases (caspase-3, and caspase-7) through its interaction via the BIR3 and BIR2 domains.10 Because the effector caspases are the common downstream caspases for both the extrinsic pathway (death receptor pathway) and the intrinsic pathway (mitochondria pathway), XIAP could block both pathways potently.
Increased XIAP has been reported in a variety of human tumors, including esophageal carcinoma,11 clear cell renal carcinoma,12 ovarian carcinoma,13 lymphoma,14 and HCC.15 In some cases, this expression was found to be associated with reduced survival.12 Although overexpression of XIAP in cancer cells is linked to increased resistance to apoptosis, exactly how this survival advantage benefits tumors at various stages of tumor development and progression is less clear. Nevertheless, it seems that suppression of XIAP could be beneficial in cancer therapy.16 Indeed, anti-sense oligonucleotides against XIAP have been developed and found to possess therapeutic effects in both in vivo and in vitro studies.17, 18 Currently, a novel second-generation anti-sense oligonucleotide against XIAP, AEG35156, is under assessment in multiple phase I trials in cancer patients.19
Here we investigated the expression of XIAP in established HCC cell lines and in HCC patients and demonstrated the role of this anti-apoptosis molecule in metastasis, tumor recurrence, and therapeutic outcome of HCC patients.
Materials and Methods
Animals, Cell Lines, and Reagents.
Male BALB/c nude mice (nu/nu; Shanghai Institute of Material Medica, Chinese Academy of Science, Shanghai, China) at the age of 4 to 6 weeks were housed in laminar flow cabinets under specific pathogen-free conditions. The mice were cared for and handled according to the recommendations of the National Institute of Health Guidelines for Care and Use of Laboratory Animals. Experimental protocol was approved by Shanghai Medical Experimental Animal Care Committee.
The metastasis-capable human HCC cell lines MHCC97L and HCCLM3 were established through consecutive in vivo selection based on lung metastasis and in vitro clonal expansion.20 The human HCC cell line SMMC7721 has a very low metastatic potential.21 All three cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and standard supplements. HCCLM3 cells stably expressing a short hairpin RNA (shRNA) against XIAP was established via retroviral infection and puromycin selection.
All chemical reagents were obtained from Sigma (St. Louis, MO). The following antibodies were used: anti-XIAP (for immunoblot: BD Biosciences, San Diego, CA; for immunohistochemistry: R&D system, Minneapolis, MN), anti- Bcl-XL(Cell Signaling, Boston, MA), anti-Bcl-2 (clone 6A8, BD Biosciences), anti-Mcl-1 (BD Biosciences), anti-c-IAP1, anti-c-IAP2, anti-nuclear factor kappaB p65RelA, anti-Bak, anti-Bax, and anti-p53 (Santa Cruz Biotech, Santa Cruz, CA), anti-Survivin (R&D Systems), anti-Bid,22 and anti-β-actin (Sigma).
Recombinant adenovirus expressing human XIAP (Ad-Y5-XIAP) or the control viral vector (Ad-Y5) were prepared in the University of Pittsburgh Biotechnology core facility as described previously.23
RNA Interference–Mediated Down-Regulation of XIAP.
For cell culture study, a small interfering RNA (siRNA) hairpin duplex against human XIAP (NM_001167, base 241-259, GTGGTAGTCCTGTTTCAGC; Cell Signaling) was used to knock down XIAP in cultured cell lines. A random scrambled siRNA (GGAUAACCUCAAUUCGGUU; Invitrogen) was used as a negative control. To establish stable cell lines expressing shRNA against XIAP, the same oligonucleotides were cloned into the RNA interference–Ready pSIREN-RetroQ retroviral vector system (Clontech, Mountain View, CA). For retroviral infection, PA317 packaging cells were transfected with 10 μg of the appropriate retroviral constructs using Polyfect (Qiagen). The culture supernatants containing the viral particles were collected 24 hours after transfection and filtered for subsequent use.
Analysis of Apoptosis, Invasiveness, and Metastasis.
Cells undergoing apoptosis were determined by the typical nuclear morphology of condensation and fragmentation, following the staining with Hoechst 33342 (5 μg/mL). Caspase-3 activities were determined as previously described.24 The membrane invasion assay was performed in Matrigel-coated invasion chambers (Becton Dickinson Labware, Franklin Lakes, NJ) as previously described.25 Dulbecco's modified Eagle's medium with 10% fetal bovine serum was added to the lower chamber as a chemoattractant, and 2.5 × 104 cells were plated in the upper chamber. After incubation at 37°C in a humidified 5% CO2 atmosphere for 48 hours, the cells in the upper chamber and on the Matrigel were mechanically removed with a cotton swab. The cells on the outer surface of the membrane were stained with Diff-Quick stain (Dade Behring Inc., Newark, DE) according to the manufacturer's instructions. The invading cells were examined, counted, and photographed by digital microscopy (Nikon Eclipse TE 200, Melville, NY). Six fields were counted per filter in each group, and the experiment was repeated three times.
For in vivo metastasis analysis, HCC cells (5 × 106) in 0.2 mL phosphate-buffered saline were injected subcutaneously into the left upper flank region of the nude mice. The mice were sacrificed 42 days later and the lungs were removed for histopathological examinations. Tumor volume at the injection site was calculated by the formula v = (a × b2)/2 (where a = the larger diameter, b = the perpendicular diameter). In addition, each lung was fixed in 10% formalin buffer and paraffin-embedded. Five serial sections were made for each lung block, and the total number of microscopic lung metastatic foci was then determined as previously described.20
Patient samples were obtained following informed consent according to an established protocol approved by the Ethic Committee of Fudan University. Data do not contain any information that may lead to the identification of the patients.
Matched pairs of primary HCC samples and adjacent liver tissues were used for the construction of a tissue microarray (Shanghai Biochip Co., Ltd. Shanghai, China) as previously described.26 Briefly, duplicates of 1-mm diameter cylinders from two different areas, the center of the tumor tissue and the liver tissue adjacent to the tumor, a total of four punches, were included in each case, along with different controls, to ensure reproducibility and homogeneous staining of the slides. Sections of 4-μm thickness were placed on 3-aminopropyltriethoxysilane–coated slides for subsequent staining with an anti-XIAP antibody using a manufacturer-recommended two-step Envision method (DAKO, Carpinteria, CA).
Comparisons of quantitative data were analyzed by Student t test between two groups, or by one-way analysis of variance for multiple groups. Categorical data were analyzed by Fisher's exact test. The Kaplan-Meier method was used to determine survival probability, and the differences were assessed by the log-rank test. Cox multivariate regression analysis was used to determine independent prognostic factors. All analyses were performed with SPSS software (version 13.0, SPSS, Chicago, IL).
Differential Response of HCC Cell Lines to Apoptosis Is Correlated with Their Metastatic Capabilities.
To understand whether the metastasis capability of HCC cells could be correlated with the ability to survive, we compared the apoptotic response of three human HCC cell lines, which had previously been characterized for their different metastatic capability.20, 21, 27 A number of apoptotic stimuli were applied, which include a death receptor ligand, tumor necrosis factor alpha (TNF-α); a DNA-damaging agent, etopside; a general protein kinas inhibitor, staurosporine (STS); a proteasome inhibitor, MG132 and an oxidant, H2O2. These agents are capable of inducing apoptosis through the extrinsic death receptor pathway or the intrinsic mitochondria pathway.
We found that the most metastatic HCCLM3 cells were also the most resistant, whereas the least metastatic SMMC7721 cells were the most sensitive (Fig. 1A). The extent of apoptotic response of MHCC97L cell, which had an intermediate level of metastatic capability, was between those of SMMC7721 and HCCLM3 cells. The dose–response pattern of the three cell lines as illustrated in the case of H2O2 treatment clearly indicated their differential sensitivities in correlation with their metastatic capability (Fig. 1B). Thus, although SMMC7721 were sensitive to H2O2 even at the low dose of 250 mM, MHCC97L cells became sensitive only at the high dose of 600 μM. Conversely, HCCLM3 cells were resistant to H2O2 even at the high dose. This dose-dependent response pattern could be also observed in other treatments (data now shown). Furthermore, the time-response patterns were also clearly correlated well with the metastatic capability with SMMC7721 cells dying more rapidly than the other two cell lines (Fig. 1C).
Activation of caspases is a hallmark of apoptosis. We found that caspase-3 activities in the treated cells were correlated with the nuclear staining assay, with the highest detected in HCCLM3 cells (Fig. 1D). Caspase-8 and capase-9 activities were similar to those of caspase-3 (data not shown). The apoptosis of these cells could be suppressed by carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (z-VAD-fmk), a general caspase inhibitor (data not shown). Taken together, it seems that cells that are more metastatic are also more apoptosis-resistant.
Differential Expression of XIAP May Account for the Variable Resistance of HCC Cells to Apoptosis.
We examined whether there could be differential expression of key apoptotic regulatory molecules that would correlate with the observed variations in apoptosis sensitivity in these HCC cells. We found that there were no differences in the expression of several anti-apoptosis molecules, such as Bcl-XL, Bcl-2, c-IAP1, c-IAP2, Survivin, and a nuclear factor kappaB subunit, p65RelA (Fig. 2A), and prodeath molecules, such as Bax and Bid (Fig. 2B).
Paradoxically, the most sensitive cell line, SMMC7721, expressed a higher level of Mcl-1, an anti-death Bcl-2 family protein, and a lower level of prodeath molecule, p53, suggesting that these molecules might not be responsible for the differential apoptosis sensitivity. Although SMMC7721 cells expressed a higher level of a prodeath Bcl-2 family protein, Bak, the level of Bak did not show a noticeable difference between HCCLM3 and MHCC97L cells (Fig. 2B), which rendered it harder to attribute the differential apoptotic response of these two cell lines to this factor, although we could not rule it out. However, the expression of XIAP, a prosurvival molecule of the IAP family, seemed to better correlate with the apoptosis sensitivity with the highest expression in HCCLM3 cells and lowest expression in the SMMC7721 cells (Fig. 2A). Because of this close correlation, we reasoned that XIAP would likely be a major factor determining the apoptosis behavior of these cells among the various contributing molecules. We thus decided to focus our study on XIAP.
To confirm the role of XIAP, we introduced a specific siRNA into HCCLM3 cells, which effectively knocked down the expression XIAP (>80%) in this cell line without affecting the expression of other IAP molecules, such as c-IAP1 and c-IAP2 (Fig. 3A). Correspondingly, this led to a significant increase in the apoptotic response (Fig. 3B). Conversely, overexpression of XIAP in SMMC7721 cells (Fig. 3C) significantly raised the resistant level to multiple apoptotic stimuli (Fig. 3D). These findings thus suggest that the different levels of XIAP in these cell lines could at least in part explain their differential sensitivity to apoptotic stimulation.
Modulation of the Expression of XIAP Can Alter the Metastatic Outcome of HCC Cells.
Because the level of XIAP expression in the three established HCC lines correlated with their metastatic capability, we investigated whether modulating the XIAP level could affect the metastasis in vivo. Toward this end, we established HCCLM3 cells stably expressing a shRNA construct against XIAP. The same short hairpin sequence as used in siRNA-mediated knockdown experiment was cloned into an RNA interference–ready pSIREN vector. Transient transfection of the vector into HCCLM3 demonstrated that this vector worked well in knocking down XIAP, resulting in more than 80% of inhibition in 120 hours (Fig. 4A). This sequence was then cloned into the RNA interference–ready pSIREN-retroviral vector, from which a specific retrovirus was made for infection into HCCLM3 cells. Stable clones were selected that consistently expressed a much lower level of XIAP, compared with the cells expressing the control shRNA (Fig. 4B).
A total of 5 × 106 XIAP-knock-down HCCLM3 cells or control cells were subcutaneously injected into the flank of nude mice, respectively. Necropsy at the 42nd day indicated that the average tumor volume at the injection sites was not statistically different between the control and XIAP-knock-down group (0.69 ± 0.15 cm3 versus 0.66 ± 0.26 cm3, P = 0.865, one-way analysis of variance). Although pulmonary metastasis could be detected in both groups at 100% rate (5/5 in each group), which were confirmed by histological examination (Fig. 4C), the number of metastatic foci revealed a significantly reduced ability of HCCLM3 cells to establish individual metastatic foci (approximately 40% reduction; Fig. 4D). These observations thus indicated that altered expression of XIAP did not affect significantly the growth of tumor cells at the primary site, but rather affect the outcome of the metastasis as revealed by the difference in the metastatic foci in the lung.
It is likely that XIAP could do so by providing survival advantage to the metastatic cells via its anti-apoptosis effect (Figs. 1 and 3), which would be important during the transit of these cells from the primary site to the secondary site and during the establishment of the colony at the secondary site.5–7 XIAP could alter other biological behavior of HCC cells, which might be also important for metastasis. Thus, we investigated the impact of XIAP on the invasiveness of HCC cells in vitro. SMMC7721 cells that were treated with recombinant adenovirus expressing XIAP and HCCLM3 cells that were treated with siRNA against XIAP were analyzed for the invasiveness in Matrigel (Fig. 5). Compared with the control group, SMMC7721 cells overexpressing XIAP had a significantly increased ability to pass through the Matrigel, indicating an increased invasive behavior. As anticipated, HCCLM3 cells were more invasive than SMMC7721 cells. However, knocking down XIAP in HCCLM3 resulted in a much reduced ability to pass through Matrigel. Taken together, it is likely that XIAP could affect the metastatic outcome by several mechanisms.
Expression of XIAP in HCC Correlates with a Poorer Prognosis in Patients.
These findings also suggest that XIAP could be an important factor in determining clinical outcomes of HCC patients. To determine whether this could be the case, we examined the expression of XIAP in 192 HCC samples in a tissue microarray by immunohistochemistry (Table 1). Most HCC samples (89.6%) were found to be highly positive for XIAP, which was observed primarily in the cytoplasm (Fig. 6A). In contrast, less than half of the adjacent liver tissues (45.8%) expressed XIAP (P < 0.01, Fisher's exact test), suggesting that high XIAP expression was more of a characteristic of the HCC cells.
|XIAP Staining||Tumor (n = 192)||Adjacent Liver Tissue (n = 192)||P Value|
These 192 paired samples were from advanced HCC patients who underwent total liver resection followed by orthotopic liver transplantation (OLT). They had been followed up for a median length of 58 months for the clinical outcome. Segregation of these patients into the XIAP-positive and XIAP-negative groups did not reveal significant correlations with any single clinicopathological parameters (Table 2). However, these groups were significantly correlated with Milan criteria, which consider both the number and the size of the tumor nodules.28 Thus, patients who exceeded the Milan criteria were more likely to have an increased XIAP expression. The Milan criteria are widely used to predict the clinical outcome of HCC patients post-OLT.28 In fact, when the 192 patients were grouped according to the Milan criteria, those exceeding the Milan criteria had a significantly worse overall survival and disease-free survival than those matching the criteria (P = 0.00, data not shown). Consistently, the 1-year, 2-year, and 3-year overall survival and disease-free survival after OLT were much worse for the XIAP-positive group than the XIAP-negative group (Table 3; Fig. 6B,C). Because of the correlation of XIAP expression and Milan criteria, the prognostic value of XIAP expression is to a large degree overlapped with that of Milan criteria. Thus, for patients who matched the Milan criteria, further segregation based on XIAP expression did not lead to significant differences in overall and disease-free survival; even the trend remained the same (Fig. 6D,E). However, in patients who exceeded the Milan criteria, those with increased XIAP expression had significantly shorter disease-free survival (Fig. 6F,G), indicating that XIAP expression could provide additional prognostic values beyond the Milan criteria in advanced cases.
|Clinicopathological Variables||Tumor XIAP Expression||P Value*|
|Maximal tumor size||≤5 cm||16||109||0.214|
|Child-Pugh score‡||Class A||17||128||0.524|
|Survival Measurement||XIAP Expression||P Value|
|1-year overall survival (%)||100.0 ± 0.0||76.1 ± 3.3||0.021|
|2-year overall survival (%)||93.3 ± 6.4||61.8 ± 3.9|
|3-year overall survival (%)||93.3 ± 6.4||57.5 ± 4.4|
|1-year disease-free survival (%)||100.0 ± 0.0||69.4 ± 3.6||0.003|
|2-year disease-free survival (%)||100.0 ± 0.0||65.6 ± 3.8|
|3-year disease-free survival (%)||100.0 ± 0.0||63.4 ± 4.3|
Finally, we performed Cox multivariate regression analysis to determine the independent prognostic factors among the 13 important clinicopathological factors (Table 2). We found that positive XIAP expression in HCC, the presence of microsatellite lesions, and a larger tumor size could be independent prognostic factors for both overall survival and disease-free survival (Table 4). Overall, patients with XIAP-positive HCC had approximately four times higher risk than patients with XIAP-negative HCC for tumor recurrence and for a lower survival rate. Taken together, these findings suggest that XIAP expression is an important predicting factor for metastatic recurrence in HCC patients, which in turn affects their survival.
|Overall Survival||Disease-Free Survival|
|Wald||P Value||95% CI for RR||RR||Wald||P Value||95% CI for RR||RR|
|XIAP expression (positive versus negative)||3.7248||0.050||0.979||16.412||4.008||4.1981||0.040||1.066||17.855||4.363|
|Microsatellite lesions (present versus absent)||6.7969||0.009||1.172||3.073||1.898||9.0329||0.003||1.293||3.386||2.092|
|Maximal tumor size (>5 cm versus <5 cm)||3.8698||0.049||1.002||2.635||1.625||6.8798||0.008||1.178||3.109||1.914|
Hepatocellular carcinoma is one of the most prevalent cancers worldwide. Despite recent advances in diagnosis and treatment, the outcome is still far from optimal. Total liver resection followed by liver transplantation has emerged as an effective treatment for HCC, particularly for patients with advanced cirrhosis.29 Excellent results can be achieved when this combination of regimens is performed following a strict or slightly loosened set of Milan criteria.28, 30 Although the 5-year survival rate seemed to be extended with a reduced recurrence rate, compared with the treatment by partial liver resection,28, 30–32 once the recurrence is established the treatment is still difficult and the prognosis is dismal. Recurrence in this setting is attributable to metastasis from the original tumors, which occurs before the procedure. However, the mechanism of metastasis and the factors affecting the metastasis in HCC are not fully understood, which impedes the development of effective treatments.
Metastasis is a complicated process, involving multiple steps.5 Generally, metastasis is an inefficient process, and only a small percentage of cancer cells can manage through these steps to establish a metastatic tumor.6 Studies have indicated that resistance to cell death is intrinsically associated with metastasis.7 Our initial studies on three HCC cell lines with different metastasis potentials indicated that they indeed possessed different sensitivity to a diverse array of intrinsic and extrinsic apoptosis stimulation. Notably, a lower sensitivity was associated with a higher metastatic potential. Thus, the highly metastatic HCCLM3 cells were much more resistant to apoptosis than the weakly metastatic SMMC-7721 cells. MHCC97L cells fell between in terms of its metastatic capability and apoptosis resistance.
A number of factors could account for the differences in apoptosis sensitivity. Earlier studies showed that ratio of the anti-death versus the prodeath members of the Bcl-2 family proteins was critical to the response of many types of cancer cells to therapeutic agent-induced apoptosis.33 Increased expression of Bcl-2, Bcl-XL, or Mcl-1 has been associated with poor therapeutic response and poor prognosis. However, in the three HCC cells that we investigated, the expression of the anti-death and prodeath Bcl-2 family proteins neither seemed to differ significantly nor seemed to correlate with their apoptosis sensitivity (Fig. 2).
In contrast, we observed that the expression level of XIAP in these cell lines was closely correlated with their apoptosis sensitivity. The IAP family consists of multiple members.8, 16 However, XIAP may be the only member that has the authentic caspase-suppressive effect under normal conditions.9 Expression of XIAP in tumors has been well studied.11–14 Our observation in the three HCC cell lines indicates that only XIAP level is functionally discriminative (Fig. 2). Indeed, increasing XIAP expression in the sensitive SMMC-7721 cells significantly enhanced their resistance to multiple apoptotic stimuli. Conversely, down-regulation of XIAP in the resistant HCCLM3 cells significantly sensitized them to apoptosis.
Would the differential expression of XIAP contribute to the different metastatic capacity observed in these cell lines, perhaps because of their differential sensitivity to apoptosis? Our studies reveal that XIAP level is correlated with enhanced lung metastasis in vivo. These effects are likely attributable to an increased resistance to apoptosis, although XIAP may have other effects affecting metastasis, such as increased invasiveness. To determine that this effect of XIAP was not an artifact of experimental manipulation, we examined clinical HCC samples for XIAP expression. Furthermore, we investigated the impact of XIAP expression on HCC recurrence and survival in patients undergoing total liver resection followed by orthotopic liver transplantation. This therapeutic regimen provides a good model to study metastasis, because any recurrent foci must be derived from metastatic cells of the original tumors before or during the resection of the affected liver.
In 192 such cases that were followed, we found that XIAP expression was elevated in 89.6% of the HCC samples. To determine whether XIAP expression could be in general increased in HCC samples, we had also examined 75 additional HCC samples from patients who presented minor conditions without the need of total liver resection and OLT. These samples were also from consecutive cases in a randomly determined period of time. We found increased XIAP expression in 77.3% of the cases (58/75). A high rate of XIAP expression (approximately 70%) in liver cancer had also been reported in another independent work.15 Thus, in general, XIAP expression is increased in most HCC samples.
Most importantly, patients with XIAP-positive tumors had an increasing risk of recurrence and thus a significantly reduced disease-free survival rate. This led to a reduction in overall postsurgery survival rate as well. XIAP expression is a powerful independent prognostic factor. This finding is consistent with the results from cell culture and animal studies and with the notion that XIAP is an important factor affecting tumor metastasis and recurrence. Interestingly, XIAP expression has the similar prognostic values as the Milan criteria, likely because increased XIAP expression is significantly more likely to be seen in patients who exceed the Milan criteria, that is, in patients with more tumors or larger tumors. However, XIAP expression could reveal further survival difference even in those advanced patients.
Early studies had shown that XIAP expression was also negatively correlated with the prognosis of clear cell renal carcinoma,12 and that Survivin expression was negatively correlated with the prognosis of patients with HCC.34 Our study is consistent with these studies indicating the procancer role of IAP molecules and clearly supports the notion that metastasis can be a key step where suppression of apoptosis by XIAP can be contributive.
In conclusion, through a series of studies using HCC cell lines, animal models, and HCC patient samples, we have established the importance of XIAP in resistance to apoptosis, invasiveness, metastasis, and tumor recurrence in HCC patients. These effects seem to be interconnected, and the survival advantage conferred by XIAP may be the major mechanism. Thus, XIAP can be an important biomarker for HCC recurrence and could be therapeutically targeted to reduce HCC metastasis and recurrence.
The authors thank Professor Xiao-Ling Xu (Shanghai Institute of Foreign Trade) for assistance with the statistical analysis.
- 21Clonal analysis of a hepatocarcinoma cell line: an experimental model of tumor heterogeneity. Cancer Research on Prevention and Treatment 1995; 22: 65–67., , .